On August 4, 2025 BerGenBio ASA (the "Company") and Oncoinvent ASA ("Oncoinvent") reported regarding the contemplated combination of the Company, Oncoinvent and BerGenBio Norge AS though a statutory triangular merger (the "Merger") (Press release, BerGenBio, AUG 4, 2025, View Source;approval-of-the-merger-plan-and-the-fully-underwritten-rights-issue,c4214207 [SID1234654737]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

An extraordinary general meeting of the Company was held on 12:00 hours (CEST) today by electronic means through Lumi AGM. All items on the agenda were resolved in accordance with the board of directors’ and the nomination committee’s proposals, including, but not limited to, approval of the merger plan dated 30 June 2025 (the "Merger Plan") and the fully underwritten rights issue in the Company to raise gross proceeds of NOK 130 million.

As announced by Oncoinvent today, the Merger Plan has been approved by the extraordinary general meeting of Oncoinvent. As a consequence, the decision to approve the Merger will now be filed with the Norwegian Register of Business Enterprises. Completion of the Merger remains subject to customary terms and conditions, as further described in the Merger Plan and the joint stock exchange announcement made on 30 June 2025.

The minutes from the extraordinary general meeting are attached hereto and will also be made available on the Company’s website www.bergenbio.no.

For further information regarding the Merger and the complete terms and conditions for the Merger, please see the Merger Plan with appendices available on www.bergenbio.no.